Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Feb 17;102(13):1036–1043. doi: 10.1136/heartjnl-2015-308120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

PMC Copyright notice

Treatment comparisons between patients allocated to rivaroxaban and warfarin. Treatment comparisons between patients allocated to rivaroxaban and warfarin for safety endpoints among SVD subtypes and for patients with no SVD. Events per 100 patient-years, unadjusted. p Values for any difference among groups are based on Cox proportional hazards models. Patients in each treatment are shown separately. For results of detailed statistical analyses, see online supplementary table S1. NMCR, non-major clinically relevant; pt-years, patient years; SVD, significant valve disease; MR or AR, mitral or aortic regurgitation.